Mesenchymal Stem Cells Market by Type, Indication, Source of Isolation, Application

List of Tables

[189 Pages Report] The Mesenchymal Stem Cells Market size was estimated at USD 3.51 billion in 2023 and expected to reach USD 3.98 billion in 2024, at a CAGR 13.63% to reach USD 8.59 billion by 2030.

Mesenchymal stem cells (MSCs) are multipotent stromal cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, and adipocytes. These cells are identified by their ability to adhere to plastic surfaces when cultured under specific conditions and by the expression of certain surface markers. MSCs are harvested from various tissues, including bone marrow, adipose tissue, umbilical cord blood, and dental pulp. The major factors driving the expansion of their use include their regenerative potential, immunomodulatory properties, and their use in treating various diseases, such as osteoarthritis, cardiovascular disease, and graft-versus-host disease. Additionally, their potential in emerging regenerative medicine applications and as delivery vehicles for gene therapy has further catalyzed research and industry interest. However, there is a risk of immune rejection and potential for malignant transformation with the use of MSCs. To address these issues, standardization of MSC isolation and culture techniques is critical, as well as the development of robust protocols for in vitro expansion and quality control. Advances in tissue engineering and the development of 3D bioprinting technologies may allow for the construction of complex tissues and organs using MSCs. Additionally, the growing emphasis on personalized medicine is likely to lead to more targeted and effective MSC-based therapies.

KEY MARKET STATISTICS
Base Year [2023]	USD 3.51 billion
Estimated Year [2024]	USD 3.98 billion
Forecast Year [2030]	USD 8.59 billion
CAGR (%)	13.63%

Type: Immunological safety and personalized nature of autologous MSCs to make them beneficial for long-term treatments

Allogeneic MSCs are derived from a donor, which are then expanded and stored for use in different recipients. These cells have an advantage in scalability and immediate availability, which is critical in acute care scenarios. Allogeneic MSCs are often indicated in cases where patients require immediate intervention and may not have the time or ability to donate their own cells. In addition, individuals with compromised health or certain genetic disorders may benefit more from allogeneic MSCs to avoid the risks of using their potentially unhealthy cells. Autologous MSCs are harvested from the patient's own body, which diminishes the likelihood of immune rejection and avoids the ethical considerations associated with donor sourcing. Autologous MSCs are preferred in chronic conditions or when treatments are planned, such as for degenerative diseases. This personalization ensures compatibility and a lower risk of immune response.

Indication: Substantial research and development activities on MSCs for the treatment of CVDs

The need for mesenchymal stem cells (MSCs) in bone and cartilage repair is driven by the increasing prevalence of osteoarthritis, rheumatoid arthritis, and osteoporosis, as well as the necessity for improved healing of bone fractures. MSCs are pivotal for their potential to differentiate into osteoblasts and chondrocytes, thereby providing a regenerative option for repairing damaged bone and cartilaginous tissues. MSCs represent a novel therapeutic approach for cancer treatment, particularly due to their homing capabilities to tumor sites and their potential to deliver anti-cancer agents. Cardiovascular diseases (CVD) are a leading cause of death globally, and MSCs have gained attention for their potential to regenerate damaged heart tissue. The need for this application is pressing due to the limited regenerative capacity of the cardiac tissue. Graft-versus-host disease (GvHD) is a severe complication of hematopoietic stem cell transplantation. MSCs have immunomodulatory properties that make them a suitable treatment for managing GvHD. MSCs' immunomodulatory effects serve as a potential therapy for autoimmune and inflammatory diseases such as multiple sclerosis, lupus, and Crohn's disease. These conditions have a high need for new therapies due to their chronic nature and the inadequacy of existing treatments. Liver diseases, such as cirrhosis and hepatitis, can lead to liver failure, for which liver transplantation is the only definitive treatment. MSC therapies could offer a less invasive alternative by promoting liver regeneration and fibrosis repair.

Source of Isolation: High cell yield and established therapeutic use of bone-marrow derived MSC

Adipose tissue-derived MSCs (AD-MSCs) are obtained from fat tissues, often during liposuction procedures. They are abundant and easy to harvest, with a high yield of MSCs per gram of tissue. AD-MSCs exhibit a strong capacity for differentiation, making them ideal for regenerative medicine and cosmetic applications. Bone marrow-derived MSCs (BM-MSCs) are one of the most extensively studied MSC types due to their high differentiation potential. They are often used in treating hematological diseases and repairing bone and cartilage. Cord blood-derived MSCs are collected from the umbilical cord blood after childbirth, a non-invasive and ethically uncontroversial source. They are less mature than MSCs from other sources, which may have implications for their immunomodulatory functions. Mesenchymal stem cells isolated from the fallopian tube are a novel source with a promising future in regenerative medicine due to their embryonic-like properties. Fetal liver-derived MSCs have been identified for their high proliferation rate and potential to generate a variety of cell types. Their use is primarily research-focused, with particular interest in liver diseases and hepatic regeneration. Lung-derived MSCs are valuable for studying and treating respiratory diseases due to their site-specific advantages. Mesenchymal stem cells obtained from peripheral blood have the advantage of being harvested through a less invasive process. They offer a non-invasive alternative to bone marrow and adipose tissue sources, but the MSCs found in peripheral blood are in far lower concentrations, which can complicate isolation and limit their clinical applications.

Application: Benefits of MSCs in disease modeling and drug discovery due to their ability to mimic human diseases and test drug efficacy

MSCs are increasingly being utilized in disease modeling to understand the pathophysiology of various disorders. Researchers prioritize MSCs for their ability to differentiate into multiple cell types and for their immunomodulatory properties. MSCs play a crucial role in the early phases of drug development and discovery. Their differentiation capabilities enable researchers to observe the effects of new drugs on various cell types derived from MSCs. This is essential for discovering new therapies and understanding drug mechanisms. Stem cell banking has emerged as an important application for MSCs, with private and public banks offering storage services for future therapeutic use. Tissue engineering is a growing field where MSCs are essential for the development of biological substitutes to repair or replace damaged tissues. MSCs are also used for in vitro toxicology studies to evaluate the safety of chemicals and drugs. MSCs' multipotency makes them particularly suited for predicting toxicity in multiple cell types.

Regional Insights

In the Americas, particularly the United States and Canada, there is a robust presence of biotechnology firms engaged in mesenchymal stem cell (MSCs) research and therapy development, supported by significant investment and favorable regulatory pathways for cell therapy products. These countries are major in clinical trials involving MSCs, focusing on applications such as osteoarthritis, wound healing, and graft-versus-host disease, propelled by the FDA's progressive stance on stem cell therapies and advanced healthcare infrastructure. The APAC region, led by countries such as China, Japan, and South Korea, showcases a dynamic and rapidly growing interest in MSCs, with governments actively promoting regenerative medicine as a key area for scientific advancement. APAC companies are investing heavily in scaling up manufacturing capabilities and in establishing international collaborations to enhance both research and clinical application of MSCs. The EMEA region presents a mixed scenario, with European countries adhering to stringent regulatory standards similar to those in the Americas. The European Medicines Agency (EMA) offers a comprehensive regulatory framework that ensures the safety and efficacy of MSC products. Nonetheless, Europe is home to several pioneering companies and research institutions dedicated to stem cell research, with a focus on quality and adherence to Good Manufacturing Practice (GMP) standards.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Mesenchymal Stem Cells Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Mesenchymal Stem Cells Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Mesenchymal Stem Cells Market, highlighting leading vendors and their innovative profiles. These include AMS Biotechnology, Astellas Pharma Inc., Athersys, Inc., Axol Biosciences Ltd., BrainStorm Cell Therapeutics Inc., Cell Applications, Inc., Celprogen, Inc., Cyagen Biosciences, Inc., Cytori Therapeutics Inc., Genlantis, Inc., Globus Medical, Hope Biosciences, LLC, Lonza Group AG, Merck KGaA, Mesoblast Limited, Neuromics, Pluri Biotech Ltd., PromoCell GmbH, R&D Systems, Inc., ScienCell Research Laboratories, Inc., Smith & Nephew PLC, Stemcell Technologies Inc., Stemedica Cell Technologies, Inc., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Inc., and Vericel Corporation.

Market Segmentation & Coverage

This research report categorizes the Mesenchymal Stem Cells Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Allogeneic
- Autologous

Indication
- Bone & Cartilage Repair
- Cancer
- Cardiovascular Disease
- GvHD
- Inflammatory & Immunological Disease
- Liver Diseases

Source of Isolation
- Adipose Tissues
- Bone Marrow
- Cord Blood
- Fallopian Tube
- Fetal Liver
- Lung
- Peripheral Blood

Application
- Disease Modeling
- Drug Development & Discovery
- Stem Cell Banking
- Tissue Engineering
- Toxicology Studies

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Mesenchymal Stem Cells Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Mesenchymal Stem Cells Market?

3. What are the technology trends and regulatory frameworks in the Mesenchymal Stem Cells Market?

4. What is the market share of the leading vendors in the Mesenchymal Stem Cells Market?

5. Which modes and strategic moves are suitable for entering the Mesenchymal Stem Cells Market?

Product Code: MRR-B973EDD5ED66

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growth in Mesenchymal Stem Cell-Based Research
  - 5.1.1.2. Rising Geriatric Population Coupled with Growth in Chronic Diseases
  - 5.1.1.3. Continuously Evolving Landscape of Stem Cell Therapies
- 5.1.2. Restraints
  - 5.1.2.1. Lack of Standardized and Regulated Delivery of Stem Cell Therapy
- 5.1.3. Opportunities
  - 5.1.3.1. Emerging Applications of Mesenchymal Stem Cells
  - 5.1.3.2. Growing Collaborations and Partnerships and Advancing Therapeutic Innovations of Mesenchymal Stem Cell Products
- 5.1.4. Challenges
  - 5.1.4.1. Ethical & Safety Issues Associated with Human MSC Therapy
5.2. Market Segmentation Analysis
- 5.2.1. Type: Immunological safety and personalized nature of autologous MSCs to make them beneficial for long-term treatments
- 5.2.2. Indication: Substantial research and development activities on MSCs for the treatment of CVDs
- 5.2.3. Source of Isolation: High cell yield and established therapeutic use of bone-marrow derived MSC
- 5.2.4. Application: Benefits of MSCs in disease modeling and drug discovery due to their ability to mimic human diseases and test drug efficacy
5.3. Market Trend Analysis
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization

6. Mesenchymal Stem Cells Market, by Type

6.1. Introduction
6.2. Allogeneic
6.3. Autologous

7. Mesenchymal Stem Cells Market, by Indication

7.1. Introduction
7.2. Bone & Cartilage Repair
7.3. Cancer
7.4. Cardiovascular Disease
7.5. GvHD
7.6. Inflammatory & Immunological Disease
7.7. Liver Diseases

8. Mesenchymal Stem Cells Market, by Source of Isolation

8.1. Introduction
8.2. Adipose Tissues
8.3. Bone Marrow
8.4. Cord Blood
8.5. Fallopian Tube
8.6. Fetal Liver
8.7. Lung
8.8. Peripheral Blood

9. Mesenchymal Stem Cells Market, by Application

9.1. Introduction
9.2. Disease Modeling
9.3. Drug Development & Discovery
9.4. Stem Cell Banking
9.5. Tissue Engineering
9.6. Toxicology Studies

10. Americas Mesenchymal Stem Cells Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Mesenchymal Stem Cells Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Mesenchymal Stem Cells Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Cellcolabs Announces Partnership With REPROCELL for Research And GMP Grade MSC And MSC Derivatives
- 13.3.2. PromoCell Launches PromoExQ MSC Growth Medium XF for GMP-Compliant Isolation and Expansion of Mesenchymal Stem Cells
- 13.3.3. Pluristyx and Stemmatters Announce Partnership to Develop and Manufacture iPSC-derived MSC Banks

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio